lipocine inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products. the company develops drugs based on hydroance, a drug delivery technology. it primarily focuses on developing oral versions of several hormones for use in men and women health. the company’s lipid-based technology platform offers non-invasive delivery solutions for small polar organics and macromolecules. it also offers custom drugs for pharmaceutical/biotechnology companies. lipocine inc. was founded in 1997 and is headquartered in salt lake city, utah.
Company profile
Ticker
LPCN
Exchange
Website
CEO
Mahesh Patel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
MARATHON BAR CORP
SEC CIK
Corporate docs
Subsidiaries
Lipocine Operating Inc. ...
IRS number
990370688
LPCN stock data
Latest filings (excl ownership)
8-K
Other Events
7 Mar 24
8-K
Results of Operations and Financial Condition
7 Mar 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Lipocine to Present at 36th Annual Roth Conference
6 Mar 24
8-K
Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154
12 Feb 24
8-K
Lipocine and Verity Pharma Enter into License Agreement
18 Jan 24
8-K
Other Events
8 Jan 24
8-K
Lipocine to Present at Biotech Showcase 2024
19 Dec 23
S-3
Shelf registration
22 Nov 23
8-K
Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023
13 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.07 mm | 4.07 mm | 4.07 mm | 4.07 mm | 4.07 mm | 4.07 mm |
Cash burn (monthly) | 314.00 k | (no burn) | 2.35 mm | 1.49 mm | 868.68 k | 973.55 k |
Cash used (since last report) | 1.77 mm | n/a | 13.23 mm | 8.40 mm | 4.89 mm | 5.48 mm |
Cash remaining | 2.30 mm | n/a | -9.15 mm | -4.33 mm | -821.31 k | -1.41 mm |
Runway (months of cash) | 7.3 | n/a | -3.9 | -2.9 | -0.9 | -1.5 |
Institutional ownership, Q2 2023
9.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 3 |
Closed positions | 21 |
Increased positions | 0 |
Reduced positions | 21 |
13F shares | Current |
---|---|
Total value | 2.35 bn |
Total shares | 477.54 k |
Total puts | 0.00 |
Total calls | 87.20 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 221.46 k | $1.12 bn |
BLK Blackrock | 80.30 k | $404.70 mm |
Geode Capital Management | 48.83 k | $244.15 mm |
Wealth Effects | 29.27 k | $147.54 mm |
Bridgeway Capital Management | 24.67 k | $123.33 mm |
STT State Street | 18.63 k | $93.13 mm |
Kestra Advisory Services | 16.70 k | $84.18 mm |
Two Sigma Investments | 11.03 k | $55.61 mm |
Susquehanna International | 10.99 k | $54.97 mm |
Renaissance Technologies | 10.40 k | $52.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Krista Fogarty | Common Stock | Grant | Acquire A | No | No | 0 | 991 | 0.00 | 1,727 |
8 Mar 24 | Mahesh V. Patel | Common Stock | Grant | Acquire A | No | No | 0 | 4,893 | 0.00 | 112,311 |
25 May 23 | Mahesh V. Patel | Common Stock | Buy | Acquire P | No | No | 5.03 | 8,706 | 43.79 k | 107,418 |
10 May 23 | Higuchi John W. | Common Stock Common Stock | Grant | Acquire A | No | No | 0.2656 | 30,000 | 7.97 k | 156,000 |
10 May 23 | Jill M. Jene | Stock Option Common Stock | Grant | Acquire A | No | No | 0.2656 | 30,000 | 7.97 k | 62,000 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
13 Mar 24
Lipocine Announces Confirmation Of Dosing Regimen For Pivotal Study Of LPCN 1154
6 Feb 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Jan 24
Lipocine And Verity Pharma Enter Into License Agreement For TLANDO Franchise In The U.S. And Canada; Lipocine To Receive $11M License Fee; Up To $259M In Development And Commercial Sales Milestones
18 Jan 24
Press releases
Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
7 Mar 24
Lipocine to Present at 36th Annual Roth Conference
6 Mar 24
Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals
2 Feb 24
Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada
18 Jan 24